Overview

A Study in Patients With Major Depressive Disorder

Status:
Active, not recruiting
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
Phase:
Phase 2
Details
Lead Sponsor:
Chase Therapeutics Corporation
Treatments:
Ondansetron
Pramipexole